Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 25 · below the Ichimoku cloud · RSI 37 · MACD below its signal
| 10.54 | 52-week high | +117.27% |
| 6.01 | Previous month high | +23.89% |
| 5.40 | Previous week high | +11.32% |
| 5.37 | R3 (classic) | +10.63% |
| 5.18 | R2 (classic) | +6.84% |
| 5.02 | R1 (classic) | +3.42% |
| 5.00 | Previous day high | +3.06% |
| 4.91 | Previous month low | +1.15% |
| 4.85 | Price now | |
| 4.83 | Pivot | −0.36% |
| 4.67 | S1 (classic) | −3.78% |
| 4.65 | Previous day low | −4.14% |
| 4.65 | Previous week low | −4.14% |
| 4.48 | S2 (classic) | −7.57% |
| 4.32 | S3 (classic) | −10.99% |
| 1.90 | 52-week low | −60.83% |
None of the 29 investors followed here reported a position in CNSP in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CNSP trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Levin RamiChief Executive Officer | — | 4.8K | — |
| May 17, 2026 | Charles Faith L.Director | Purchase at price 4.79 per share. | 7.1K | $34.00K |
| May 17, 2026 | Fisher MichalDirector | Purchase at price 5.00 per share. | 2K | $10.00K |
TimeframesDown on the hourly, daily and monthly, mixed on the weekly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.3 | -44.3 | -23.2 | -5.0 | 139.6 | -12.1 | 21.7 | 2.8 | -11.4 | -8.5 | −7.6% | ||
| 2025 | -20.8 | -48.8 | -44.0 | -20.2 | -5.1 | -19.9 | -19.4 | -22.3 | 45.2 | -14.4 | -9.9 | -24.4 | −92.7% |
| 2024 | -80.5 | 12.1 | 30.2 | -41.7 | 2.4 | -85.4 | -79.9 | -50.5 | -16.6 | -14.5 | 0.0 | 7.1 | −99.8% |
| 2023 | -7.9 | -16.3 | -45.9 | 51.0 | 21.9 | 21.2 | 1.3 | -24.3 | -33.3 | 81.6 | 0.5 | -38.9 | −47.1% |
| 2022 | -14.4 | -35.1 | -12.6 | -0.9 | -10.4 | -7.6 | -21.4 | 10.9 | -26.6 | -10.6 | -36.9 | -20.8 | −88.6% |
| 2021 | -3.4 | 52.9 | -9.1 | -16.3 | -7.5 | 5.9 | -12.2 | -1.2 | -12.4 | -7.4 | -18.8 | -37.3 | −60.6% |
| 2020 | 9.1 | -13.7 | -43.5 | 36.7 | -7.3 | -19.5 | -13.1 | 15.6 | -18.1 | -4.4 | 33.2 | -20.5 | −54.9% |
| 2019 | -4.4 | −4.4% |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.